Titel	Veröffentlichungsdatum	Sprache	Zitate
ACTIVLIM: A Rasch-built measure of activity limitations in children and adults with neuromuscular disorders	2007/06/01	English	82
Statin myotoxicity: A review of genetic susceptibility factors	2014/01/01	English	82
Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies	2017/03/01	English	82
Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice	2006/12/01	English	81
Current status of the congenital myasthenic syndromes	2012/02/01	English	81
Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies	2011/06/01	English	81
Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy	2015/09/01	English	81
Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1	2011/02/01	English	81
Passive avoidance behaviour deficit in the mdx mouse	1991/01/01	English	81
Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France	2012/10/01	English	81
Inclusion body myositis	2010/02/01	English	80
Spinal muscular atrophy: A changing phenotype beyond the clinical trials	2017/10/01	English	79
Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene	2007/04/01	English	79
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease	2009/02/01	English	78
196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands	2013/11/01	English	78
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review	2017/03/01	English	78
Epidemiology of myasthenia gravis in Ontario, Canada	2016/01/01	English	77
Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease	2008/06/01	English	77
Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)	2006/05/01	English	77
Predictors of severe chest infections in pediatric neuromuscular disorders	2006/05/01	English	77
Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation	2010/07/01	English	77
Distal myopathies – New genetic entities expand diagnostic challenge	2012/01/01	English	77
TREAT-NMD workshop: Pattern recognition in genetic muscle diseases using muscle MRI	2012/10/01	English	76
Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy	2010/04/01	English	76
Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France	2008/11/01	English	76
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy	2014/03/01	English	76
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial	2011/06/01	English	75
Targeted next-generation sequencing assay for detection of mutations in primary myopathies	2016/01/01	English	75
Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids	2018/11/01	English	75
Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy	2012/01/01	English	75